CellSource Co

CellSource Co CapEx/D&A

The CapEx to Depreciation Ratio of CellSource Co (4880.T) as of Oct 28, 2026 is 8.97. In the previous year, CapEx to Depreciation Ratio was 13.66 — a change of -34.33% (lower).

CapEx/D&A

8.97

YoY

-34.33%

Last updated:

CapEx to Depreciation Ratio of CellSource Co is 2024 8.97 . CapEx to Depreciation Ratio of CellSource Co was 2023 13.66 . It decreases by -34.33% lower compared to the previous year.

The CellSource Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
44.49 JPY
Jan 1, 2018
8.83 JPY
Jan 1, 2019
7.44 JPY
Jan 1, 2020
3.75 JPY
Jan 1, 2021
4.49 JPY
Jan 1, 2022
7.21 JPY
Jan 1, 2023
13.66 JPY
Jan 1, 2024
8.97 JPY
The CellSource Co CapEx/D&A history
YEARCapEx/D&AYoY
8.97-34.33%
13.66+89.35%
7.21+60.54%
4.49+19.86%
3.75-49.58%
7.44-15.76%
8.83-80.16%
44.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

CapEx to Depreciation Ratio of CellSource Co is 8.97 in 2024.

CapEx to Depreciation Ratio of CellSource Co changed from 13.66 to 8.97, representing a -34.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co